These high response rates to a specific inhibitor emphasize that BCR::ABL1 remains the driving force in most patients with CML-CP, even in later lines of therapy, and highlight the need for highly potent, well-tolerated, and targeted TKIs. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.